Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental HIV treatments news

Show

From To
Studies confirm long-term effectiveness of new single-tablet regimens

The newest once-daily, all-in-one HIV combination pills can maintain undetectable viral load for two years and counting, according to a set of studies presented at IDWeek 2018

Published
1 hour ago
By
Liz Highleyman
Wide range of views about switching to weekly, monthly or biannual ART

Two-thirds of people taking combination antiretroviral therapy (cART) would be interested in switching to a once-weekly oral regimen should it become available, according to American research published in

Published
15 October 2018
By
Michael Carter
Long-acting injectable implant shows promise for HIV treatment and prevention

The long-acting antiretroviral drug formulation, developed by UNC School of Medicine researchers, is injected under the skin and forms into a solid implant that dissolves slowly to release anti-HIV medication over time.

Published
09 October 2018
From
University of North Carolina
Doravirine combination works well as a switch option

A combination pill containing doravirine (Delstrigo) maintains undetectable viral load in people with well-controlled HIV who switched therapy, and continues to provide sustained viral suppression at 96

Published
08 October 2018
By
Liz Highleyman
Dual-antibody combination therapy produces three to seven months of viral suppression without pills

A group of researchers have for the first time used infusions of antibodies to produce prolonged suppression of HIV viral load without antiretroviral therapy (ART) in the

Published
08 October 2018
By
Gus Cairns
Merck’s HIV Therapy DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate) Meets Primary Efficacy Endpoint in Phase 3 DRIVE-SHIFT Study Evaluating Switch to DELSTRIGO from Other Antiretroviral Treatment Regimens

The study met its primary endpoint of non-inferior efficacy as measured by the proportion of participants who switched to DELSTRIGO and had plasma HIV-1 RNA levels <50 copies/mL at Week 48 compared to the proportion of participants who continued on their baseline regimen and had HIV-1 RNA levels <50 copies/mL at Week 24.

Published
05 October 2018
From
Merck press release
Janssen Reports Switching to SYMTUZA™ Results in Maintained High Virologic Suppression and No Resistance Development up to 96-Weeks in Virologically Suppressed Adults with HIV-1

Results from the pivotal Phase 3 EMERALD study demonstrate that in adults with HIV-1 who are virologically suppressed, switching to SYMTUZA™ resulted in maintained high virologic suppression (91%, 692/763) and low virologic failure (1%, 9/763) at week 96 (per FDA-Snapshot); low cumulative virologic rebound (3.1%, 24/763); and no resistance development, up to 96-weeks.

Published
05 October 2018
From
Janssen press release
Vedolizumab could be used to target latent HIV harboring in gut

Vedolizumab, a first-line treatment for inflammatory bowel disease that targets the alpha4beta7 protein, might be an important tool in the search for a cure for HIV, according to research published in Science Translational Medicine.

Published
04 October 2018
From
Healio
Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy

Biktarvy Showed High Efficacy and a Demonstrated Tolerability Profile Through 96 Weeks

Published
03 October 2018
From
Gilead press release
HIV drug Symtuza® receives NHS England funding

The Janssen Pharmaceutical Companies of Johnson & Johnson have announced that NHS England (NHSE) will provide critical funding for Symtuza® (darunavir/cobicistat/emtricitabine/tenofovir alafenamide [D/C/F/TAF]), a once-daily darunavir-based single tablet regimen (STR), for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents aged 12 years and older with a body weight of at least 40 kg.

Published
28 September 2018
From
Pharmafield
← First12345...106Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.